# RO4929097 in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma That Can Be Removed by Surgery

> **NCT01216787** · PHASE2 · WITHDRAWN · sponsor: **National Cancer Institute (NCI)**

## Conditions studied

- Stage IIIB Melanoma
- Stage IIIC Melanoma
- Stage IV Melanoma

## Interventions

- **DRUG:** gamma-secretase/Notch signalling pathway inhibitor RO4929097
- **OTHER:** pharmacological study
- **PROCEDURE:** therapeutic conventional surgery
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT01216787
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2010-09
- **Primary completion:** 2011-11
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study drug not available.
- **Last updated:** 2013-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01216787

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01216787, "RO4929097 in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma That Can Be Removed by Surgery". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01216787. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*